Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SGLT-2 Inhibitors: Focus on Dapagliflozin.

Cardiology in review·2024
Same author

The Impact of the Apolipoprotein E Genotype on Cardiovascular Disease and Cognitive Disorders.

Cardiology in review·2024
Same author

The Significance of Parametric Mapping in Advanced Cardiac Imaging.

Cardiology in review·2024
Same author

Transcatheter Aortic Valve Implantation for Aortic Regurgitation: A Comprehensive Review.

Cardiology in review·2024
Same author

Harnessing the Power of AI: A Comprehensive Review of Left Ventricular Ejection Fraction Assessment With Echocardiography.

Cardiology in review·2024
Same author

Fontan-Associated Liver Disease: A Review.

Cardiology in review·2024
Same journal

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on "Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on: "Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Calcium channel blockers: differences between subclasses.

William H Frishman1

  • 1Department of Medicine, New York Medical College, Valhalla, New York 10595, USA. JOANNE_PRYOR@NYMC.EDU

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|October 23, 2009
PubMed
Summary
This summary is machine-generated.

Calcium channel blockers (CCBs) offer distinct effects. Non-dihydropyridines show advantages for kidney disease patients, and fixed-dose combinations with ACE inhibitors improve blood pressure control and adherence.

More Related Videos

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
11:32

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry

Published on: September 28, 2016

Related Experiment Videos

Last Updated: Jun 19, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
11:32

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry

Published on: September 28, 2016

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Calcium channel blockers (CCBs) are a class of drugs with a shared mechanism of action but differing subclass effects.
  • Dihydropyridine (DHP) CCBs are potent vasodilators, while non-dihydropyridine CCBs exhibit stronger negative inotropic effects.

Purpose of the Study:

  • To compare the pharmacological effects of different calcium channel blocker subclasses.
  • To evaluate the potential benefits of non-DHP CCBs in managing chronic kidney disease and diabetic nephropathy.
  • To highlight the advantages of fixed-dose combinations of CCBs with ACE inhibitors.

Main Methods:

  • Comparative analysis of CCB subclasses' pharmacological profiles.
  • Review of clinical data regarding CCB use in specific patient populations.
  • Evaluation of fixed-dose combination therapies.

Main Results:

  • Dihydropyridine CCBs demonstrate greater vasodilatory potency.
  • Non-dihydropyridine CCBs show more significant negative inotropic effects.
  • Both subclasses effectively lower blood pressure, with non-DHPs offering advantages in chronic kidney disease and diabetic nephropathy.
  • Fixed-dose combinations with ACE inhibitors provide sustained blood pressure control, reduce adverse events, and improve patient adherence.

Conclusions:

  • CCB subclasses possess distinct pharmacological properties influencing their clinical applications.
  • Non-dihydropyridine CCBs may be preferred for patients with chronic kidney disease and diabetic nephropathy.
  • Fixed-dose CCB and ACE inhibitor combinations represent an effective strategy for managing hypertension and improving patient outcomes.